JP2015523569A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523569A5
JP2015523569A5 JP2015520541A JP2015520541A JP2015523569A5 JP 2015523569 A5 JP2015523569 A5 JP 2015523569A5 JP 2015520541 A JP2015520541 A JP 2015520541A JP 2015520541 A JP2015520541 A JP 2015520541A JP 2015523569 A5 JP2015523569 A5 JP 2015523569A5
Authority
JP
Japan
Prior art keywords
prostate cancer
level
keratin
subject
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523569A (ja
JP6352909B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048373 external-priority patent/WO2014004931A1/en
Publication of JP2015523569A publication Critical patent/JP2015523569A/ja
Publication of JP2015523569A5 publication Critical patent/JP2015523569A5/ja
Application granted granted Critical
Publication of JP6352909B2 publication Critical patent/JP6352909B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520541A 2012-06-27 2013-06-27 前立腺癌の診断および処置におけるマーカーの使用 Expired - Fee Related JP6352909B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US61/665,201 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US61/672,090 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US61/673,094 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US61/702,523 2012-09-18
US201261718081P 2012-10-24 2012-10-24
US201261718080P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
US61/718,064 2012-10-24
US61/718,081 2012-10-24
US61/718,080 2012-10-24
PCT/US2013/048373 WO2014004931A1 (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109092A Division JP6581247B2 (ja) 2012-06-27 2018-06-07 前立腺癌の診断および処置におけるマーカーの使用

Publications (3)

Publication Number Publication Date
JP2015523569A JP2015523569A (ja) 2015-08-13
JP2015523569A5 true JP2015523569A5 (enExample) 2016-09-08
JP6352909B2 JP6352909B2 (ja) 2018-07-04

Family

ID=49783880

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015520541A Expired - Fee Related JP6352909B2 (ja) 2012-06-27 2013-06-27 前立腺癌の診断および処置におけるマーカーの使用
JP2018109092A Expired - Fee Related JP6581247B2 (ja) 2012-06-27 2018-06-07 前立腺癌の診断および処置におけるマーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018109092A Expired - Fee Related JP6581247B2 (ja) 2012-06-27 2018-06-07 前立腺癌の診断および処置におけるマーカーの使用

Country Status (15)

Country Link
US (3) US20140038838A1 (enExample)
EP (1) EP2867375B1 (enExample)
JP (2) JP6352909B2 (enExample)
KR (1) KR20150023904A (enExample)
CN (1) CN104583422A (enExample)
AU (1) AU2013284448B2 (enExample)
BR (1) BR112014032728A2 (enExample)
CA (1) CA2877721A1 (enExample)
EA (1) EA201492284A1 (enExample)
ES (1) ES2720763T3 (enExample)
IL (1) IL236482A0 (enExample)
MX (1) MX360236B (enExample)
NZ (1) NZ703411A (enExample)
SG (1) SG11201408651TA (enExample)
WO (1) WO2014004931A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
RU2678135C1 (ru) * 2014-02-05 2019-01-23 Фуджиребио Диагностикс Аб Композиция и способ для детектирования злокачественного неопластического заболевания
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP4242329A3 (en) * 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
JP6983819B2 (ja) * 2016-06-03 2021-12-17 エトゥビクス コーポレーション 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
EP3490677A4 (en) * 2016-07-07 2020-05-13 Berg LLC LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
KR102405789B1 (ko) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물
CN109608537B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
CN109608536B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
KR102497196B1 (ko) * 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
CN114134223B (zh) * 2021-12-02 2022-10-11 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒
CN114460297A (zh) * 2022-01-17 2022-05-10 珠海中科先进技术研究院有限公司 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (de) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4208422A1 (de) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren
PT938320E (pt) 1996-03-26 2010-09-22 Michael S Kopreski Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
US6207380B1 (en) 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
WO2000023100A2 (en) 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ATE452989T1 (de) 2000-03-27 2010-01-15 Univ Jefferson Zusammensetzungen und methoden zur identifizierung von krebszellen
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
CA2439854A1 (en) 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003234932A1 (en) 2002-05-21 2003-12-02 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (de) 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
EP2500440B1 (en) 2002-12-20 2015-12-16 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
CA2519630A1 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
CA2527285A1 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
JP2007507204A (ja) 2003-07-29 2007-03-29 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
CN1743849A (zh) 2004-09-03 2006-03-08 上海透景生命科技有限公司 一种多肿瘤标志物并行检测的方法及试剂盒
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006106823A1 (ja) 2005-03-31 2006-10-12 Japan Science And Technology Agency 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
JP5166250B2 (ja) 2005-05-25 2013-03-21 エクスプレッション、パソロジー、インコーポレイテッド 組織病理学的に処理した生物学的試料からのプロテオームの適用範囲を増加させるための、液体組織標品を用いたマルチプレックス方法
EP1907845A4 (en) * 2005-05-25 2009-03-04 Expression Pathology Inc DIAGNOSIS OF ILLNESSES AND SUFFERING BY ANALYSIS OF HISTOPATHOLOGICALLY PREPARED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US20070122856A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
EP1963860A1 (en) * 2005-12-19 2008-09-03 University of Hull Cancer screening test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (ja) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
EP2064552B1 (en) 2006-09-07 2011-08-31 Universitätsklinikum Hamburg-Eppendorf Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells
RU2473555C2 (ru) 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
ATE555212T1 (de) * 2007-03-02 2012-05-15 Biosante Pharmaceuticals Inc Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
US8889361B2 (en) 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
AU2008307579A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
ES2372442T3 (es) 2007-12-10 2012-01-19 F. Hoffmann-La Roche Ag Seprasa como marcador para cáncer.
CN105734128B (zh) 2008-02-01 2021-05-18 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
AU2009270851A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
WO2013022995A2 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA2742286C (en) 2008-11-12 2016-08-09 F. Hoffmann-La Roche Ag Pacap as a marker for cancer
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
EP2380024B1 (en) 2008-12-22 2014-06-11 Roche Diagnostics GmbH Armet as a marker for cancer
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012100536A (ja) 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
EP2403877B1 (en) 2009-03-06 2015-05-06 Klaus Tschira Stiftung GgmbH Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
JP5892794B2 (ja) * 2009-10-02 2016-03-23 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
WO2011053837A1 (en) 2009-10-29 2011-05-05 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) * 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012015904A2 (en) * 2010-07-28 2012-02-02 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same
CA2807209C (en) * 2010-08-16 2019-09-17 Mount Sinai Hospital Markers of the male urogenital tract
US20140148350A1 (en) * 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN106706914B (zh) 2010-09-09 2018-10-19 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及单克隆抗体
CN103384824B (zh) 2010-12-06 2016-02-03 Thd股份公司 癌症诊断方法及其用途
WO2012083338A1 (en) 2010-12-24 2012-06-28 Map Diagnostics Pty Ltd. Selective reaction monitoring (srm) derived protein profiles for cancer and other pathologic entities
EP2668503B1 (en) 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in lung cancer patient management
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
KR101320633B1 (ko) 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
WO2013039477A1 (en) 2011-09-12 2013-03-21 University Of South Alabama Non-invasive methods of detecting target molecules
CA2865335A1 (en) 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
ES2875535T3 (es) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (zh) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
WO2014160499A2 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
SE538211C2 (sv) 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
WO2015042465A1 (en) 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Similar Documents

Publication Publication Date Title
JP2015523569A5 (enExample)
Qi et al. Circulating long non-coding RNAs in cancer: current status and future perspectives
Pin et al. The role of proteomics in prostate cancer research: biomarker discovery and validation
Cornu et al. Urine TMPRSS2: ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer
Klein et al. Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study
Payne et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma
Maxwell et al. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors
JP2017507320A5 (enExample)
Udovicich et al. 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends
Summers et al. Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection
JP2017524130A5 (enExample)
Guzzo et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance
Muley et al. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung
JP6857185B2 (ja) 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
JP2015518152A (ja) 前立腺がんの検出用バイオマーカーの定量
WO2016014705A1 (en) Characterization of melanoma using a molecular signature
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
Zhao et al. Cardia and non-cardia gastric cancer have similar stage-for-stage prognoses after R0 resection: a large-scale, multicenter study in China
ten Heuvel et al. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression
Tay et al. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
JP2025512761A (ja) 断片化プロファイルを用いる癌を監視する方法
Xin et al. Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma
Sun et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy
US12275994B2 (en) Methods and compositions for the analysis of cancer biomarkers
Syed et al. Current management strategy for active surveillance in prostate cancer